Zibotentan (ZD4054)
98%
- Product Code: 64076
CAS:
186497-07-4
| Molecular Weight: | 424.43 g./mol | Molecular Formula: | C₁₉H₁₆N₆O₄S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Zibotentan is primarily investigated for its potential in treating cancer, particularly prostate cancer. It functions as an endothelin receptor antagonist, specifically targeting the endothelin A receptor. By blocking this receptor, zibotentan inhibits the signaling pathways that promote tumor growth and progression. This makes it a candidate for slowing the spread of cancer cells and reducing tumor size in advanced stages of prostate cancer. Clinical trials have explored its use both as a monotherapy and in combination with other treatments, such as chemotherapy or hormone therapy, to enhance efficacy. Its application is particularly focused on patients with metastatic castration-resistant prostate cancer, where it aims to improve survival rates and quality of life.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Light Yellow Powder or Crystals |
| PURITY | 97.5-100 |
| NMR | Consistent with structure |
| Infrared spectrum | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | £289.50 |
+
-
|
| 0.050 | 10-20 days | £1,040.38 |
+
-
|
| 0.250 | 10-20 days | £2,715.85 |
+
-
|
Zibotentan (ZD4054)
Zibotentan is primarily investigated for its potential in treating cancer, particularly prostate cancer. It functions as an endothelin receptor antagonist, specifically targeting the endothelin A receptor. By blocking this receptor, zibotentan inhibits the signaling pathways that promote tumor growth and progression. This makes it a candidate for slowing the spread of cancer cells and reducing tumor size in advanced stages of prostate cancer. Clinical trials have explored its use both as a monotherapy and in combination with other treatments, such as chemotherapy or hormone therapy, to enhance efficacy. Its application is particularly focused on patients with metastatic castration-resistant prostate cancer, where it aims to improve survival rates and quality of life.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
£0.00
£0.00
Total :